Saturday 17 October 2026
Export TBIO’s income statement to Excel — free account
Telesis Bio Inc.
TBIO Healthcare Medical Devices
Revenue growth for five consecutive years, operating cash flow growth for three.
0.04
0.00
0.00%
Follow TBIO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 110.83 | 19.44 | 5.40 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | — | — | — | — | — | 462.60 | 203.76 | 59.76 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 108 | 42 | 229 | 142 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.06 | 0.26 | 0.12 | 0.19 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 5 | 7 | 11 | 27 | 28 | ||||
| Gross margin, % | — | — | — | — | — | (84.99) | 55.12 | 38.93 | 56.84 | 61.62 | |||||
| EBT | — | — | — | — | — | (8) | (18) | (39) | (48) | (48) | |||||
| EBT margin, % | — | — | — | — | — | (172.78) | (273.80) | (352.66) | (176.59) | (173.40) | |||||
| Net income | — | — | — | 0 | — | (8) | (18) | (39) | (48) | (48) | |||||
| Depreciation | — | — | — | — | — | 1 | 2 | 2 | 3 | 16 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.16 | 23.65 | 10.90 | 16.75 | 16.57 | ||||
| Earnings | — | — | — | — | — | (0.28) | (64.76) | (38.49) | (29.68) | (29.50) | |||||
| Cash flow | — | — | — | — | — | (0.22) | (55.31) | (36.22) | (23.63) | (20.89) | |||||
| Capex | — | — | — | — | — | 0.00 | (0.73) | (1.83) | (2.73) | (1.18) | |||||
| Free cash flow | — | — | — | — | — | (0.22) | (56.04) | (38.05) | (26.36) | (22.07) | |||||
| Book value | — | — | — | — | — | (0.26) | (91.55) | 89.61 | 28.43 | 0.14 | |||||
| Shares, m | — | — | — | — | — | 29 | 0 | 1 | 2 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | 13.80 | 13.80 | 17.83 | 1.40 | 0.43 | |||||
| P/B | — | — | — | — | — | 0.00 | 0.00 | 2.17 | 0.82 | 49.44 | |||||
| EV/Sales | — | — | — | — | — | 19.27 | 19.27 | 11.61 | 0.52 | (0.08) | |||||
| EV/FCF | — | — | — | — | — | (6.45) | (6.45) | (3.33) | (0.33) | 0.06 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (6) | (15) | (37) | (39) | (35) | ||||
| Capex | — | — | — | — | — | 0 | 0 | (2) | (4) | (2) | |||||
| Free cash flow | — | — | — | — | — | (6) | (16) | (39) | (43) | (37) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 30 | 12 | 83 | 42 | 22 | ||||
| Total debt | — | — | — | — | — | 44 | 3 | 14 | 20 | 5 | |||||
| Net debt | — | — | — | — | — | 15 | (10) | (69) | (24) | (14) | |||||
| Shareholders’ equity | — | — | — | — | — | (8) | (25) | 91 | 47 | 0 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (21.42) | (67.04) | (54.44) | (49.05) | (64.60) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | (100.19) | (129.18) | 0.00 | |||||
| ROE | — | — | — | — | — | 110.65 | 70.74 | (119.27) | (70.58) | (209.49) | |||||
Negative figures in brackets.
Fiscal years to Dec 2023 · latest quarter Sep 2024
Charts ten years each
Telesis Bio Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| WOK WORK Medical Technology Group LTD | $6.0M | — | — | — | — | −948.94% (below 0%: shrinking) | — | — | Compare |
| AMIX Autonomix Medical, Inc. | $5.7M | — (loss-making) | — | — | n/m | −36.10% (below 0%: shrinking) | — | 0.00% | Compare |
| NVNO enVVeno Medical Corporation | $5.5M | — (loss-making) | — (loss-making) | +0.32% (above 0%: growing) | n/m | +4.60% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CODX Co-Diagnostics, Inc. | $5.3M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| TBIO Telesis Bio Inc. | $5.3M | — (loss-making) | — (loss-making) | −61.79% (below 0%: shrinking) | n/m | −17.96% (below 0%: shrinking) | 64.43% | (349.74%) | |
| VNRX VolitionRX Limited | $5.3M | — (loss-making) | — (loss-making) | −1.97% (below 0%: shrinking) | n/m | +18.58% (above 0%: growing) | 100.00% | (1,042.39%) | Compare |
| TRIB Trinity Biotech PLC | $5.1M | — (loss-making) | — (loss-making) | +43.28% (above 0%: growing) | n/m | +75.24% (above 0%: growing) | 35.43% | (24.53%) | Compare |
| VVOS Vivos Therapeutics, Inc. | $4.8M | — (loss-making) | — (loss-making) | +34.90% (above 0%: growing) | n/m | +16.44% (above 0%: growing) | 57.31% | (93.63%) | Compare |
| INBS Intelligent Bio Solutions Inc. | $4.8M | — (loss-making) | 5.4× | +51.10% (above 0%: growing) | n/m | −31.59% (below 0%: shrinking) | 43.23% | (360.19%) | Compare |
| Median of peers | $5.3M | — | — | +18.43% | — | +10.52% | 50.27% | (93.63%) |
Telesis Bio Inc. (TBIO) key facts
- Telesis Bio Inc. (TBIO) is a Medical Devices company in the Healthcare sector.
- As of October 15, 2026, TBIO traded at $0.04, a market capitalization of $5.3 million.
- Return on equity was −209.5% and debt-to-equity -0.23.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −4.52 (distress zone) for fiscal 2023.
Telesis Bio Inc. (TBIO) Latest News
No news at this impact. Lower the threshold for more.